HK1151525A1 - Quinazoline derivatives as raf kinase modulators and methods of use thereof raf - Google Patents
Quinazoline derivatives as raf kinase modulators and methods of use thereof rafInfo
- Publication number
- HK1151525A1 HK1151525A1 HK11105522.3A HK11105522A HK1151525A1 HK 1151525 A1 HK1151525 A1 HK 1151525A1 HK 11105522 A HK11105522 A HK 11105522A HK 1151525 A1 HK1151525 A1 HK 1151525A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- raf
- methods
- quinazoline derivatives
- kinase modulators
- raf kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6976308P | 2008-03-17 | 2008-03-17 | |
US11050808P | 2008-10-31 | 2008-10-31 | |
PCT/US2009/001659 WO2009117080A1 (en) | 2008-03-17 | 2009-03-17 | Quinazoline derivatives as raf kinase modulators and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1151525A1 true HK1151525A1 (en) | 2012-02-03 |
Family
ID=40852165
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11105522.3A HK1151525A1 (en) | 2008-03-17 | 2011-06-01 | Quinazoline derivatives as raf kinase modulators and methods of use thereof raf |
HK16104063.6A HK1216100A1 (zh) | 2008-03-17 | 2016-04-08 | 在用於治療癌症疾病中作為 激酶調節劑的 -二甲氧基喹唑啉- -基氧基 苯基 -三氟- -甲基丙烷- -基 異惡唑- -基 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16104063.6A HK1216100A1 (zh) | 2008-03-17 | 2016-04-08 | 在用於治療癌症疾病中作為 激酶調節劑的 -二甲氧基喹唑啉- -基氧基 苯基 -三氟- -甲基丙烷- -基 異惡唑- -基 |
Country Status (23)
Country | Link |
---|---|
US (5) | US8618289B2 (pt) |
EP (3) | EP3147281A1 (pt) |
JP (1) | JP5542793B2 (pt) |
KR (2) | KR101601997B1 (pt) |
CN (2) | CN106146484A (pt) |
AU (1) | AU2009226136B2 (pt) |
BR (1) | BRPI0906186A2 (pt) |
CA (2) | CA2718123C (pt) |
DK (2) | DK2947072T3 (pt) |
EA (1) | EA019350B1 (pt) |
ES (2) | ES2610989T3 (pt) |
HK (2) | HK1151525A1 (pt) |
HU (2) | HUE032873T2 (pt) |
IL (1) | IL207793A (pt) |
MX (1) | MX2010010172A (pt) |
MY (1) | MY161576A (pt) |
NZ (1) | NZ587907A (pt) |
PL (2) | PL2268623T3 (pt) |
PT (2) | PT2947072T (pt) |
SG (2) | SG10201608813PA (pt) |
SI (2) | SI2947072T1 (pt) |
WO (1) | WO2009117080A1 (pt) |
ZA (1) | ZA201006524B (pt) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011513332A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのraf阻害剤としてのn−(6−アミノピリジン−3−イル)−3−(スルホンアミド)ベンズアミド誘導体 |
AR072657A1 (es) * | 2008-02-29 | 2010-09-15 | Genentech Inc | Compuestos inhibidores de raf y metodos para su uso |
CL2009000447A1 (es) * | 2008-02-29 | 2010-01-04 | Array Biopharma Inc Y Genentech Inc | Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf. |
JP2011513329A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | RAF阻害化合物として使用されるイミダゾ[4,5−b]ピリジン誘導体 |
PL2268623T3 (pl) | 2008-03-17 | 2015-10-30 | Ambit Biosciences Corp | Pochodne chinazoliny jako modulatory kinazy RAF oraz sposoby ich zastosowania |
WO2010094695A1 (en) * | 2009-02-17 | 2010-08-26 | Boehringer Ingelheim International Gmbh | Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
HUE029771T2 (en) * | 2009-11-05 | 2017-04-28 | Ambit Biosciences Corp | Process for the preparation of imidazo [2,1-b] [1,3] benzothiazole derivatives |
US9024041B2 (en) | 2010-04-08 | 2015-05-05 | Respivert Ltd. | P38 MAP kinase inhibitors |
US8933228B2 (en) | 2010-06-17 | 2015-01-13 | Respivert, Ltd. | Respiratory formulations and compounds for use therein |
MY173181A (en) | 2011-05-13 | 2020-01-02 | Array Biopharma Inc | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors |
JP6002223B2 (ja) | 2011-08-26 | 2016-10-05 | ニューファーマ, インコーポレイテッド | 特定の化学的実体、組成物、および方法 |
US9518029B2 (en) | 2011-09-14 | 2016-12-13 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
PT2763984T (pt) | 2011-10-03 | 2016-07-25 | Respivert Ltd | 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il) ureias como inibidores da map cinase p38 |
EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
AU2012339640B2 (en) | 2011-11-14 | 2017-01-05 | Ignyta, Inc. | Uracil derivatives as AXL and c-MET kinase inhibitors |
EP2806874B1 (en) * | 2012-01-25 | 2017-11-15 | Neupharma, Inc. | Quinoxaline-oxy-phenyl derivatives as kinase inhibitors |
EP2626073A1 (en) * | 2012-02-13 | 2013-08-14 | Harmonic Pharma | Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (PDE4) |
GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
CN104602690A (zh) * | 2012-08-29 | 2015-05-06 | 默克专利股份有限公司 | 用于治疗骨关节炎的ddr2抑制剂 |
US9688635B2 (en) | 2012-09-24 | 2017-06-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
CN103102315B (zh) * | 2012-11-01 | 2016-01-20 | 云南大学 | 一种喹唑啉类芳基脲及其制备方法和用途 |
US9725421B2 (en) | 2012-11-12 | 2017-08-08 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
EP2925742B1 (en) | 2012-11-16 | 2016-10-26 | Respivert Limited | Kinase inhibitors |
US9695184B2 (en) | 2013-02-15 | 2017-07-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
EA025561B1 (ru) * | 2013-03-11 | 2017-01-30 | Игнита, Инк. | Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf |
US20160016934A1 (en) | 2013-03-14 | 2016-01-21 | Respivert Limited | Kinase inhibitors |
EP2981534B1 (en) * | 2013-04-02 | 2017-07-19 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
CN103159685A (zh) * | 2013-04-11 | 2013-06-19 | 苏州立新制药有限公司 | 4-氯-6,7-二(2-甲氧基乙氧基)喹唑啉的制备方法 |
EP3071204B1 (en) | 2013-11-20 | 2019-02-20 | SignalChem Lifesciences Corp. | Quinazoline derivatives as tam family kinase inhibitors |
JP6630280B2 (ja) | 2014-02-14 | 2020-01-15 | レスピバート・リミテツド | 抗炎症化合物としての芳香族複素環化合物 |
WO2015154064A2 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
CN106535900A (zh) * | 2014-05-06 | 2017-03-22 | 加利福尼亚大学董事会 | 使用braf抑制剂的伤口愈合 |
CN104892530A (zh) * | 2015-05-27 | 2015-09-09 | 烟台大学 | 一种含喹唑啉结构的二芳基脲类化合物及其制备方法和应用 |
CN104892529A (zh) * | 2015-05-27 | 2015-09-09 | 烟台大学 | 一种含喹唑啉结构的硫脲类化合物及其制备方法和应用 |
PT3322706T (pt) * | 2015-07-16 | 2021-03-08 | Array Biopharma Inc | Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret |
BR112018006873A2 (pt) | 2015-10-05 | 2018-11-06 | The Trustees Of Columbia University In The City Of New York | ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias |
EP3548007A4 (en) | 2016-12-01 | 2020-08-12 | Ignyta, Inc. | CANCER TREATMENT METHODS |
CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
CN108530455B (zh) | 2017-03-01 | 2021-01-12 | 北京赛特明强医药科技有限公司 | 脲取代的芳环连二噁烷并喹唑啉类化合物或药用盐或水合物及作为酪氨酸激酶抑制剂的应用 |
CN106928069B (zh) * | 2017-03-21 | 2019-03-19 | 上海玉函化工有限公司 | 一种4,5-二(2-甲氧基乙氧基)-2-硝基苯甲酸乙酯的制备方法 |
JP2020512400A (ja) * | 2017-03-23 | 2020-04-23 | クラヴィウス ファーマシューティカルズ,エルエルシー | TGFβの阻害のための三置換イミダゾールおよび治療方法 |
CN107501283B (zh) | 2017-09-13 | 2020-06-02 | 北京师范大学 | 取代芳甲杂基取代苯胺基缩乙二醇醚环代喹唑啉的制备及肿瘤治疗药物应用 |
CN109721551B (zh) * | 2017-10-30 | 2022-09-20 | 上海北卡医药技术有限公司 | 一种3,4-二氢-7-甲氧基-4-氧代喹唑啉-6-醇乙酸酯的制备方法 |
CN109721552B (zh) * | 2017-10-30 | 2022-09-20 | 上海北卡医药技术有限公司 | 一种吉非替尼的制备方法 |
JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物 |
CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
JP7061195B2 (ja) | 2018-01-18 | 2022-04-27 | アレイ バイオファーマ インコーポレイテッド | RETキナーゼ阻害剤としての置換ピラゾロ[3,4-d]ピリミジン化合物 |
JP7018224B2 (ja) | 2018-02-11 | 2022-02-10 | 北京賽特明強医薬科技有限公司 | 尿素置換芳香族環結合ジオキシノキノリン系化合物、その調製方法および使用 |
CN108358798A (zh) * | 2018-02-12 | 2018-08-03 | 黑龙江鑫创生物科技开发有限公司 | 一种微通道反应器合成厄洛替尼中间体的方法 |
WO2019241787A1 (en) * | 2018-06-15 | 2019-12-19 | The Regents Of The University Of Colorado A Body Corporate | Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use |
WO2020042972A1 (zh) * | 2018-08-27 | 2020-03-05 | 北京赛特明强医药科技有限公司 | 脲取代的芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用 |
EP3849536A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての縮合複素環式化合物 |
CN109553581B (zh) * | 2018-09-25 | 2022-01-25 | 广州六顺生物科技股份有限公司 | 取代脲化合物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
TW202043225A (zh) * | 2019-01-25 | 2020-12-01 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
BR112021015137A2 (pt) | 2019-02-12 | 2021-09-28 | Lutris Pharma Ltd. | Uso de composições tópicas de inibidor de braf para o tratamento de dermatite por irradiação |
CR20220252A (es) * | 2019-12-10 | 2022-07-11 | Hoffmann La Roche | Nuevos inhibidores de braf como rompedores de la paradoja |
WO2022159835A1 (en) | 2021-01-25 | 2022-07-28 | Halia Therapeutics, Inc. | Nek7 inhibitors |
CN113254860B (zh) * | 2021-06-04 | 2022-03-22 | 南京航空航天大学 | 一种堆芯栅元中子通量的计算方法 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
DE3209472C2 (de) | 1982-03-16 | 1984-05-17 | Degussa Ag, 6000 Frankfurt | Verfahren zur Herstellung von 3-Oxonitrilen sowie neue 3-Oxonitrile |
HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
JPS6296479A (ja) | 1985-10-23 | 1987-05-02 | Shionogi & Co Ltd | ポリフルオロアルキルイソオキサゾリルアミン類 |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
EP0835101B1 (en) | 1995-06-27 | 2004-06-09 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
DE69622183D1 (de) | 1995-11-07 | 2002-08-08 | Kirin Brewery | Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
EP1007012A4 (en) | 1996-10-01 | 2006-01-18 | Cima Labs Inc | TASTE-MASKED MICRO-CAPSULE COMPOSITION AND MANUFACTURING PROCESS |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
PT839525E (pt) | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | Preparacao de libertacao prolongada |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US6197350B1 (en) | 1996-12-20 | 2001-03-06 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US20070244120A1 (en) * | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
CN1161352C (zh) | 1998-10-08 | 2004-08-11 | 阿斯特拉曾尼卡有限公司 | 喹唑啉衍生物 |
PL206627B1 (pl) | 1999-01-22 | 2010-09-30 | Kirin Pharma Kk | Pochodna chinazoliny, jej zastosowanie i kompozycja farmaceutyczna |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
US7135466B2 (en) | 1999-12-24 | 2006-11-14 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives and drugs containing the same |
BR0113626A (pt) | 2000-08-30 | 2003-06-17 | Pfizer Prod Inc | Formulações de liberação sustentada para secretores de hormÈnio do crescimento |
ATE399766T1 (de) | 2000-10-20 | 2008-07-15 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische heterozyklen |
KR100879669B1 (ko) * | 2001-04-27 | 2009-01-21 | 기린 파마 가부시끼가이샤 | 아졸릴기를 갖는 퀴놀린 유도체 및 퀴나졸린 유도체 |
CA2454538A1 (en) | 2001-06-22 | 2003-01-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same |
CA2491191C (en) | 2002-07-15 | 2014-02-04 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
ES2925655T3 (es) | 2003-09-26 | 2022-10-19 | Exelixis Inc | Moduladores c-Met y métodos de uso |
CA2542329A1 (en) | 2003-10-16 | 2005-04-28 | Chiron Corporation | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
US20050171172A1 (en) | 2003-11-13 | 2005-08-04 | Ambit Biosciences Corporation | Amide derivatives as PDGFR modulators |
CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
US7576090B2 (en) | 2004-12-27 | 2009-08-18 | 4Sc Ag | Benzazole analogues and uses thereof |
EP1746096A1 (en) | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
AU2006328194A1 (en) | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents |
US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
CN101415688A (zh) | 2006-04-05 | 2009-04-22 | 阿斯利康(瑞典)有限公司 | 具有b-raf抑制活性的喹唑啉酮衍生物 |
WO2007113557A1 (en) | 2006-04-05 | 2007-10-11 | Astrazeneca Ab | Substituted quinazolines with anti-cancer activity |
US9110054B2 (en) | 2006-06-30 | 2015-08-18 | Discoverx Corporation | Detectable nucleic acid tag |
KR101504669B1 (ko) | 2006-10-19 | 2015-03-20 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도 |
BRPI0717773A2 (pt) | 2006-10-19 | 2013-11-05 | Signal Pharm Llc | Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula que expressa a dita quinase |
PL2268623T3 (pl) * | 2008-03-17 | 2015-10-30 | Ambit Biosciences Corp | Pochodne chinazoliny jako modulatory kinazy RAF oraz sposoby ich zastosowania |
-
2009
- 2009-03-17 PL PL09722418T patent/PL2268623T3/pl unknown
- 2009-03-17 SG SG10201608813PA patent/SG10201608813PA/en unknown
- 2009-03-17 US US12/933,402 patent/US8618289B2/en not_active Expired - Fee Related
- 2009-03-17 SG SG2013046388A patent/SG191678A1/en unknown
- 2009-03-17 PT PT151661410T patent/PT2947072T/pt unknown
- 2009-03-17 DK DK15166141.0T patent/DK2947072T3/en active
- 2009-03-17 HU HUE15166141A patent/HUE032873T2/en unknown
- 2009-03-17 PL PL15166141T patent/PL2947072T3/pl unknown
- 2009-03-17 AU AU2009226136A patent/AU2009226136B2/en not_active Ceased
- 2009-03-17 CA CA2718123A patent/CA2718123C/en not_active Expired - Fee Related
- 2009-03-17 EA EA201071089A patent/EA019350B1/ru not_active IP Right Cessation
- 2009-03-17 ES ES15166141.0T patent/ES2610989T3/es active Active
- 2009-03-17 MX MX2010010172A patent/MX2010010172A/es active IP Right Grant
- 2009-03-17 SI SI200931598A patent/SI2947072T1/sl unknown
- 2009-03-17 SI SI200931239T patent/SI2268623T1/sl unknown
- 2009-03-17 EP EP16191210.0A patent/EP3147281A1/en not_active Withdrawn
- 2009-03-17 KR KR1020107023083A patent/KR101601997B1/ko not_active IP Right Cessation
- 2009-03-17 PT PT97224182T patent/PT2268623E/pt unknown
- 2009-03-17 CA CA2972138A patent/CA2972138A1/en not_active Abandoned
- 2009-03-17 ES ES09722418.2T patent/ES2547406T3/es active Active
- 2009-03-17 BR BRPI0906186A patent/BRPI0906186A2/pt not_active Application Discontinuation
- 2009-03-17 JP JP2011500793A patent/JP5542793B2/ja not_active Expired - Fee Related
- 2009-03-17 EP EP09722418.2A patent/EP2268623B9/en not_active Not-in-force
- 2009-03-17 CN CN201610341553.2A patent/CN106146484A/zh active Pending
- 2009-03-17 EP EP15166141.0A patent/EP2947072B1/en not_active Not-in-force
- 2009-03-17 KR KR1020167000978A patent/KR101713501B1/ko active IP Right Grant
- 2009-03-17 CN CN200980116870.2A patent/CN102026985B/zh not_active Expired - Fee Related
- 2009-03-17 MY MYPI2010004046A patent/MY161576A/en unknown
- 2009-03-17 DK DK09722418.2T patent/DK2268623T3/en active
- 2009-03-17 NZ NZ587907A patent/NZ587907A/xx unknown
- 2009-03-17 HU HUE09722418A patent/HUE025197T2/en unknown
- 2009-03-17 WO PCT/US2009/001659 patent/WO2009117080A1/en active Application Filing
-
2010
- 2010-08-24 IL IL207793A patent/IL207793A/en not_active IP Right Cessation
- 2010-09-10 ZA ZA2010/06524A patent/ZA201006524B/en unknown
-
2011
- 2011-06-01 HK HK11105522.3A patent/HK1151525A1/xx not_active IP Right Cessation
-
2013
- 2013-10-08 US US14/048,655 patent/US8969587B2/en not_active Expired - Fee Related
-
2015
- 2015-01-26 US US14/605,834 patent/US9320739B2/en not_active Expired - Fee Related
-
2016
- 2016-03-18 US US15/074,671 patent/US9730937B2/en not_active Expired - Fee Related
- 2016-04-08 HK HK16104063.6A patent/HK1216100A1/zh not_active IP Right Cessation
-
2017
- 2017-06-28 US US15/636,562 patent/US10053430B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1151525A1 (en) | Quinazoline derivatives as raf kinase modulators and methods of use thereof raf | |
HK1254895A1 (zh) | 苄基苯衍生物及使用方法 | |
IL214768A0 (en) | Jak kinase modulating quinazoline derivatives and methods of use thereof | |
HK1160119A1 (en) | Kinase inhibitors and methods of use | |
EP2252293A4 (en) | KINASEHEMMER AND USE PROCESS | |
EG27167A (en) | Microemulsifiers and methods of making and using same | |
HK1172896A1 (zh) | 化合物和使用方法 | |
HK1161094A1 (en) | Compounds and methods of use | |
IL211549A0 (en) | Aminotriazolopyridines and their use as kinase inhibitors | |
IL213596A0 (en) | Heterocyclic compounds and methods of use | |
HK1147254A1 (en) | 5-anilinoimidazopyridines and methods of use 5- | |
EP2114983A4 (en) | TYROSINE KINASE ACTIVATED AXL RECEPTOR INHIBITORS AND METHODS OF MAKING AND USING THE SAME | |
HK1149933A1 (en) | Diazacarbazoles and methods of use | |
IL209548A0 (en) | Diazacarbazoles and methods of use | |
EP2242854A4 (en) | COMPOUNDS AND USES THEREOF | |
ZA201000183B (en) | Quinazolinone compounds and methods of use thereof | |
IL206125A0 (en) | Azaindolizines and methods of use | |
EP2376083A4 (en) | CHINAZOLIN INHIBITORS OF BACE 1 AND METHOD OF USE | |
EP2328603A4 (en) | APF DERIVATIVES AND USE METHOD |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20200315 |